Medpace Holdings, Inc.

NasdaqGS:MEDP

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

Location

United States

Market Cap

USD 8.65 B

Share Price

USD 297.92

Avg Daily Volume

494,823

Change (1 day)

-1.02%

Change (1 year)

-24.76%

Change (YTD)

-10.33%

Medpace Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 31.51%

Medpace Holdings, Inc. Gross Profit Margin is 31.51% for the Trailing 12 Months (TTM) ending March 31, 2025, a 12.56% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Medpace Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 27.99%, a -5.69% change year over year.
Medpace Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 29.68%, a 3.37% change year over year.
Medpace Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 28.71%, a -6.11% change year over year.
Medpace Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 30.58%, a 6.57% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Gross Profit Margin	EBIT Margin	EBITDA Margin	Net Income Margin

NasdaqGS: MEDP

Medpace Holdings, Inc.

CEO	Dr. August James Troendle M.D.
IPO Date	Aug. 11, 2016
Location	United States
Headquarters	5375 Medpace Way
Employees	5,900
Sector	🏥 Health Care
Industries Clinical Trials

Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.